CL2017003096A1 - Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis - Google Patents
Vectores virales adenoasociados para el tratamiento de mucopolisacaridosisInfo
- Publication number
- CL2017003096A1 CL2017003096A1 CL2017003096A CL2017003096A CL2017003096A1 CL 2017003096 A1 CL2017003096 A1 CL 2017003096A1 CL 2017003096 A CL2017003096 A CL 2017003096A CL 2017003096 A CL2017003096 A CL 2017003096A CL 2017003096 A1 CL2017003096 A1 CL 2017003096A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- mucopolysaccharidosis
- adeno
- viral vectors
- associated viral
- Prior art date
Links
- 208000002678 Mucopolysaccharidoses Diseases 0.000 title 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 title 1
- 239000013603 viral vector Substances 0.000 title 1
- 241000702421 Dependoparvovirus Species 0.000 abstract 1
- 208000015439 Lysosomal storage disease Diseases 0.000 abstract 1
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382297.8A EP3101125A1 (en) | 2015-06-05 | 2015-06-05 | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017003096A1 true CL2017003096A1 (es) | 2018-08-10 |
Family
ID=53398018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017003096A CL2017003096A1 (es) | 2015-06-05 | 2017-12-04 | Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10617771B2 (OSRAM) |
| EP (2) | EP3101125A1 (OSRAM) |
| JP (1) | JP6850736B2 (OSRAM) |
| KR (1) | KR102609858B1 (OSRAM) |
| CN (1) | CN108138154B (OSRAM) |
| AU (1) | AU2016273343B2 (OSRAM) |
| CA (1) | CA2988201C (OSRAM) |
| CL (1) | CL2017003096A1 (OSRAM) |
| CO (1) | CO2017012562A2 (OSRAM) |
| ES (1) | ES2790834T3 (OSRAM) |
| IL (1) | IL255939B (OSRAM) |
| MX (1) | MX386615B (OSRAM) |
| MY (1) | MY184586A (OSRAM) |
| NZ (1) | NZ738018A (OSRAM) |
| PH (1) | PH12017502192B1 (OSRAM) |
| PT (1) | PT3303576T (OSRAM) |
| RU (1) | RU2744593C2 (OSRAM) |
| TN (1) | TN2017000506A1 (OSRAM) |
| UA (1) | UA125373C2 (OSRAM) |
| WO (1) | WO2016193431A1 (OSRAM) |
| ZA (1) | ZA201708039B (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2605798A1 (en) | 2010-07-12 | 2013-06-26 | Universidad Autònoma de Barcelona | Gene therapy composition for use in diabetes treatment |
| EP2692868A1 (en) | 2012-08-02 | 2014-02-05 | Universitat Autònoma De Barcelona | Adeno-associated viral (AAV) vectors useful for transducing adipose tissue |
| EP3194430A1 (en) | 2014-09-16 | 2017-07-26 | Universitat Autònoma De Barcelona | Adeno-associated viral vectors for the gene therapy of metabolic diseases |
| WO2016087678A1 (en) | 2014-12-05 | 2016-06-09 | Universitat Autònoma De Barcelona | Viral vectors for the treatment of diabetes |
| EP3242945B1 (en) | 2015-01-07 | 2021-09-01 | Universitat Autònoma de Barcelona | Single-vector gene construct comprising insulin and glucokinase genes |
| IL262211B2 (en) | 2016-04-15 | 2024-01-01 | Univ Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
| UY37679A (es) * | 2017-04-14 | 2018-11-30 | Regenxbio Inc | Tratamiento de mucopolisacaridosis ii con iduronato-2-sulfatasa (ids) humana recombinante producida por células neurales o gliales humanas |
| TWI835747B (zh) * | 2017-09-22 | 2024-03-21 | 賓州大學委員會 | 用於治療黏多醣病 ii 型之基因治療 |
| CN108795985A (zh) * | 2018-05-31 | 2018-11-13 | 深圳市免疫基因治疗研究院 | 一种黏多糖贮积症慢病毒载体、慢病毒及其制备方法和应用 |
| CN108715867A (zh) * | 2018-05-31 | 2018-10-30 | 深圳市免疫基因治疗研究院 | 一种Sanfilippo B综合症慢病毒载体、慢病毒及其制备方法和应用 |
| EP3829619A4 (en) * | 2018-07-27 | 2022-05-18 | REGENXBIO Inc. | TREATMENT OF IVA MUCOPOLYSACCHARIDOSIS |
| US12201095B2 (en) * | 2018-11-15 | 2025-01-21 | Esteve Pharmaceuticals, S.A. | Animal model of mucopolysaccharidoses type IVA |
| TW202039856A (zh) * | 2019-03-28 | 2020-11-01 | 西班牙商艾斯提夫製藥股份有限公司 | 製造重組病毒載體之方法 |
| EP3914720B9 (en) | 2019-07-10 | 2023-09-27 | Masonic Medical Research Laboratory | Vgll4 with ucp-1 cis-regulatory element and method of use thereof |
| IL293684A (en) * | 2019-12-10 | 2022-08-01 | Takeda Pharmaceuticals Co | Adeno associated virus vectors for the treatment of hunter disease |
| BR112022019182A2 (pt) * | 2020-04-06 | 2022-11-29 | Homology Medicines Inc | Composições de vírus adeno-associadas para transferência do gene ids e métodos de uso da mesma |
| CN111718947B (zh) * | 2020-06-18 | 2022-08-23 | 舒泰神（北京）生物制药股份有限公司 | 用于治疗ⅲa或ⅲb型粘多糖贮积症的腺相关病毒载体及用途 |
| CN114480454B (zh) * | 2020-10-27 | 2024-03-29 | 华东理工大学 | 用于治疗粘多糖贮积症ⅱ型的腺相关病毒载体、药物及其应用 |
| US20240117328A1 (en) | 2021-02-10 | 2024-04-11 | Regenxbio Inc. | Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) |
| WO2022221421A2 (en) * | 2021-04-13 | 2022-10-20 | Capsida, Inc. | Aav compositions with high brain expression for treating mucopolysaccharidosis ii |
| US20240350653A1 (en) * | 2021-08-18 | 2024-10-24 | Joint-Stock Company "Generium" | Targeted delivery of therapeutic enzymes |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100762945B1 (ko) * | 2004-09-08 | 2007-10-04 | 진동규 | 동물 세포주를 이용한 이듀로네이트-설파타제의 발현 방법및 그 발현을 위한 세포주 |
| BRPI0906948B1 (pt) * | 2008-01-18 | 2023-05-16 | Biomarin Pharmaceutical, Inc | Composições compreendendo uma enzima nacetilgalactosamina-6- sulfatase (galns) recombinante humana e uso das mesmas para tratar mucopolissacaridose tipo iva, síndrome de morquio a, ou deficiência múltipla de sulfatase |
| HRP20190690T1 (hr) * | 2009-10-09 | 2019-06-28 | Armagen, Inc. | Postupci i pripravci za povećanje aktiviteta iduronat-2-sulfataze u centralnom nervnom sustavu |
| JPWO2011108451A1 (ja) * | 2010-03-01 | 2013-06-27 | 日本ケミカルリサーチ株式会社 | 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法 |
| EP2394667A1 (en) * | 2010-06-10 | 2011-12-14 | Laboratorios Del Dr. Esteve, S.A. | Vectors and sequences for the treatment of diseases |
| KR101535791B1 (ko) * | 2010-11-12 | 2015-07-10 | 주식회사 녹십자 | 개량형 이듀로네이트-2-설파타제 및 이의 용도 |
| WO2012101671A1 (en) * | 2011-01-25 | 2012-08-02 | Jcr Pharmaceuticals Co., Ltd. | Method for production of human recombinant iduronate 2-sulfatase |
| US10086043B2 (en) * | 2011-04-03 | 2018-10-02 | The General Hospital Corporation | Efficient protein expression in vivo using modified RNA (MOD-RNA) |
| AU2013243949A1 (en) * | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| US9150841B2 (en) * | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
| JP6605482B2 (ja) * | 2014-02-19 | 2019-11-13 | バイオアシス テクノロジーズ インコーポレイテッド | Ｐ９７−ｉｄｓ融合タンパク質 |
-
2015
- 2015-06-05 EP EP15382297.8A patent/EP3101125A1/en not_active Withdrawn
-
2016
- 2016-06-03 RU RU2017142006A patent/RU2744593C2/ru active
- 2016-06-03 MX MX2017015725A patent/MX386615B/es unknown
- 2016-06-03 CA CA2988201A patent/CA2988201C/en active Active
- 2016-06-03 WO PCT/EP2016/062655 patent/WO2016193431A1/en not_active Ceased
- 2016-06-03 MY MYPI2017704615A patent/MY184586A/en unknown
- 2016-06-03 NZ NZ738018A patent/NZ738018A/en unknown
- 2016-06-03 US US15/578,366 patent/US10617771B2/en active Active
- 2016-06-03 ES ES16730716T patent/ES2790834T3/es active Active
- 2016-06-03 PH PH1/2017/502192A patent/PH12017502192B1/en unknown
- 2016-06-03 JP JP2017563119A patent/JP6850736B2/ja active Active
- 2016-06-03 EP EP16730716.4A patent/EP3303576B1/en active Active
- 2016-06-03 TN TNP/2017/000506A patent/TN2017000506A1/en unknown
- 2016-06-03 UA UAA201711584A patent/UA125373C2/uk unknown
- 2016-06-03 PT PT167307164T patent/PT3303576T/pt unknown
- 2016-06-03 CN CN201680032931.7A patent/CN108138154B/zh active Active
- 2016-06-03 AU AU2016273343A patent/AU2016273343B2/en not_active Ceased
- 2016-06-03 KR KR1020187000048A patent/KR102609858B1/ko active Active
-
2017
- 2017-11-27 ZA ZA2017/08039A patent/ZA201708039B/en unknown
- 2017-11-27 IL IL255939A patent/IL255939B/en active IP Right Grant
- 2017-12-04 CL CL2017003096A patent/CL2017003096A1/es unknown
- 2017-12-05 CO CONC2017/0012562A patent/CO2017012562A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017003096A1 (es) | Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis | |
| MX2016014773A (es) | Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosomico. | |
| AR109752A1 (es) | Vectores de virus adenoasociados para el tratamiento de mucopolisacaridosis | |
| CY1123853T1 (el) | Ρυθμιστες nrf2 | |
| GT201600233A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
| CL2016001889A1 (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1. | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| MX2018016273A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| ECSP17023281A (es) | Inhibidores de mk2 y sus usos | |
| CL2016002333A1 (es) | Terapia genica para la retinitis pigmentaria. | |
| HUE057795T2 (hu) | Adenoasszociált vírus terápiás szerek központi idegrendszerbe történõ bejuttatására | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| MX2015007755A (es) | Vacunas contra virus de la influenza y sus usos. | |
| CL2016003212A1 (es) | Derivados de indolín-2-ona o pirrolo-piridín-2-ona. | |
| EA201790534A1 (ru) | Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса, предназначенного для генной терапии | |
| CL2015001733A1 (es) | Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer. | |
| CL2017001046A1 (es) | Inhibidoes del bromodominio | |
| MX2022000053A (es) | Moduladores de interaccion de sestrina-gator2 y sus usos. | |
| UY36654A (es) | Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen | |
| CL2017000372A1 (es) | Composiciones novedosas, usos y métodos para hacerlas. | |
| MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
| MX2018004542A (es) | Neoepítopos virales y sus usos. | |
| CO2020015942A2 (es) | Vectores de virus adenoasociados para el tratamiento de mucopolisacaridosis tipo iv a | |
| UY36217A (es) | Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso. | |
| CL2016001745A1 (es) | Ácido (s)-3'-metil-abscísico y ésteres del mismo |